| Budget Amount *help |
¥3,900,000 (Direct Cost: ¥3,000,000、Indirect Cost: ¥900,000)
Fiscal Year 2017: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2016: ¥2,340,000 (Direct Cost: ¥1,800,000、Indirect Cost: ¥540,000)
|
|---|
| Outline of Final Research Achievements |
Regarding radiofrequency ablation (RFA) for hepatocellular carcinoma (HCC), local recurrence is related to poor prognosis. With resected specimen, we aimed to elucidate the mechanism of high malignant potential with recurrence of hepatocellular carcinoma after radiofrequency ablation. Eighty-eight patients of HCC were divided into 2 groups; RFA group (n=10), hepatic resection was performed after local recurrence, and non-RFA group (n=78), hepatic resection was performed without prior RFA. In RFA group, mRNA of HIF-1, EpCAM, EMT marker(TGF-β, Twist, Snail-1, Vimentin), were high compared with non-RFA group. This study indicated that local recurrence after RFA accelerate HIF-1 expression, and malignant potential is enhanced through expressions of cancer stem cell and EMT markers.
|
